Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sulfonamide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Sulfonamide. Displaying page 1 of 1.
    EudraCT Number: 2007-006695-10 Sponsor Protocol Number: E2090-E044-316 Start Date*: 2008-09-23
    Sponsor Name:Eisai Limited
    Full Title: Open Label Extension Study Following Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess Efficacy and Safety of Adjunctive Zonisamide in Primary Generalized Tonic-Clonic Seizures
    Medical condition: Primary generalised tonic-clonic seizures (PGTCS) in idiopathic generalised epilepsy (IGE)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018101 Generalised tonic-clonic seizures HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-006088-23 Sponsor Protocol Number: MEK116513 Start Date*: 2012-06-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in subjects with unresectab...
    Medical condition: Metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) BE (Completed) AT (Completed) NO (Completed) IE (Completed) CZ (Completed) ES (Completed) NL (Completed) HU (Completed) FI (Completed) IT (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-003557-91 Sponsor Protocol Number: E2090-E044-315 Start Date*: 2008-07-09
    Sponsor Name:Eisai Limited
    Full Title: A double-blind, randomised, placebo-controlled, multicentre study to assess the efficacy and safety of adjunctive zonisamide in primary generalised tonic clonic seizures
    Medical condition: Primary generalised tonic-clonic seizures (PGTCS) in idiopathic generalised epilepsy (IGE)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018101 Generalised tonic-clonic seizures HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) HU (Prematurely Ended) LT (Prematurely Ended) FI (Prematurely Ended) CZ (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002515-27 Sponsor Protocol Number: E2090-E044-312 Start Date*: 2008-02-21
    Sponsor Name:Eisai Ltd
    Full Title: A double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of adjunctive zonisamide in paediatric partial onset seizures
    Medical condition: Epilepsy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065336 Partial epilepsy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) FR (Completed) LV (Completed) EE (Completed) PL (Completed) IT (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-006696-36 Sponsor Protocol Number: E2090-E044-318 Start Date*: 2008-09-05
    Sponsor Name:Eisai Limited
    Full Title: Open label Extension Study Following Double-blind, Randomized, Placebo-controlled, Multicentre Study to Assess Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures associated with Idi...
    Medical condition: myoclonic seizures in idiopathic generalised epilepsy (IGE).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054859 Myoclonic epilepsy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004955-64 Sponsor Protocol Number: E2090-S082-403 Start Date*: 2017-04-21
    Sponsor Name:Eisai Korea Inc.
    Full Title: A Multicenter Comparative Trial of Zonisamide and Topiramate as Monotherapy in Epilepsy Patients: Safety for cognitive function
    Medical condition: Epilepsy
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2012-004577-12 Sponsor Protocol Number: BRF116613 Start Date*: 2015-03-23
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: Phase II biomarker study evaluating the upfront combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib versus the combination after eight weeks of monotherapy with dabrafenib or tra...
    Medical condition: patients with metastatic and unresectable stage III or IV melanoma harbouring an activating BRAF mutation
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-003556-10 Sponsor Protocol Number: E2090-E044-317 Start Date*: 2008-07-09
    Sponsor Name:Eisai Limited
    Full Title: A double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of adjunctive zonisamide in myoclonic seizures associated with idiopathic generalised epilepsy.
    Medical condition: myoclonic seizures in idiopathic generalised epilepsy (IGE).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054859 Myoclonic epilepsy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) LT (Prematurely Ended) CZ (Completed) EE (Prematurely Ended) PL (Completed) ES (Completed) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001159-23 Sponsor Protocol Number: E2090-E044-314 Start Date*: 2008-12-04
    Sponsor Name:Eisai Limited
    Full Title: A randomized, double-blind extension study to assess long-term safety and to explore long-term efficacy of zonisamide as monotherapy in newly diagnosed partial epilepsy
    Medical condition: Epilepsy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065336 Partial epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) SK (Completed) FR (Completed) SE (Completed) DE (Completed) CZ (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-000156-40 Sponsor Protocol Number: E2090-E044-310 Start Date*: 2007-07-03
    Sponsor Name:Eisai Limited
    Full Title: A randomized, multi-centre, double-blind study, to compare the efficacy and safety of zonisamide and carbamazepine as monotherapy, in newly diagnosed partial epilepsy
    Medical condition: Epilepsy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-001499-12 Sponsor Protocol Number: BRF116013 Start Date*: 2013-04-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Children and Adolescent Subjects with Advanced BRAF ...
    Medical condition: Advanced BRAF V600-Mutation Positive Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10049280 Solid tumour LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) Outside EU/EEA ES (Completed) DE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-006087-49 Sponsor Protocol Number: MEK115306 Start Date*: 2012-04-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase III, randomized, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to dabrafenib and placebo as first-line therapy in subjec...
    Medical condition: Cutaneous melanoma - aggressive form of skin cancers.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10040808 Skin cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) GB (Completed) NL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000464-27 Sponsor Protocol Number: ART27.13-100 Start Date*: 2020-10-29
    Sponsor Name:Artelo Biosciences Limited
    Full Title: A Phase 1/2 Trial of the Synthetic Cannabinoid ART27.13 in Patients with Cancer Anorexia and Weight Loss
    Medical condition: Cancer anorexia and weight loss
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10002646 Anorexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Trial now transitioned) NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001161-41 Sponsor Protocol Number: BRF113928 Start Date*: 2012-09-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-smal...
    Medical condition: Advanced non-small cell lung cancer and BRAF mutations
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NO (Completed) DE (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000681-55 Sponsor Protocol Number: 3475-022 Start Date*: 2015-10-06
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination with Trametinib and Dabrafenib in Subjects with Advanced Melanoma
    Medical condition: advanced or metastatic melanoma - all parts of the trial advanced (unresectable and/or metastatic) solid tumours - Parts 4 and 5
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001266-15 Sponsor Protocol Number: BRF115532 Start Date*: 2013-02-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: COMBI-AD: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 muta...
    Medical condition: High-risk BRAF V600 mutation-positive melanoma after surgical resection.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) CZ (Completed) DE (Completed) NO (Completed) GB (Completed) AT (Completed) GR (Completed) IT (Completed) NL (Completed) DK (Completed) ES (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 08:50:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA